Relationship of brain natriuretic peptide with metabolic syndrome parameters: An observational study;Beyin natriüretik peptidin metabolik sendrom parametreleri ile ilişkisi: Gözlemsel bir çalışma

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 8, 2011, Pages 678-684

  Öztekin, Sanem ^a   Karakurt, Özlem ^b   Yazihan, Nuray ^c   Ünal, Ilker ^d  

^a Nallihan State Hospital   (Turkey)

^b Balikesir State Hospital   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Brain natriuretic peptide; Diastolic dysfunction; Metabolic syndrome; Regression analysis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; SEX DIFFERENCE;

EID: 83455188108     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.188     Document Type: Article

References (38)

1. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 93: 40-4. [CrossRef]
2. Voulgari C, Moyssakis I, Papazafiropoulou A, Perrea D, Kyriaki D, Katsilambros N, et al. The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab Res Rev 2010; 26:121-7. [CrossRef]
3. Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis 2010; 210: 237-42. [CrossRef]
4. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442.
5. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. for the NACB Writing Group. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007; 115: e356-75. [CrossRef]
6. Ribeiro AL. Natriuretic peptides in elderly people with acute myocardial infarction. BMJ 2009; 338:b787. [CrossRef]
7. Sezen Y, Baş M, Demirbaǧ R, Yi{dotless}ldi{dotless}z A, Çelik H, Aksoy S. N-terminal pro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndrome and left ventricular mass index. Clin Biochem 2009; 42: 1500-3. [CrossRef]
8. Li WY, Chiu FC, Chien YF, Lin JW, Hwang JJ. Association of aminoterminal pro-brain natriuretic peptide with metabolic syndrome. Intern Med 2011; 50: 1143-7. [CrossRef]
9. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46: 660-6. [CrossRef]
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97. [CrossRef]
11. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107-33. [CrossRef]
12. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, et al. Metabolic syndrome and cardiovascular disease in older people: The Cardiovascular Health Study. J Am Geriatr Soc 2006; 54: 1317-24. [CrossRef]
13. Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2008; 1: 242-8. [CrossRef]
14. de Simone G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, et al. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2009; 19: 98-104. [CrossRef]
15. Azevedo A, Bettencourt P, Almeida PB, Santos AC, Abreu-Lima C, Hense HW, et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities--cross-sectional study of the general population. BMC Cardiovasc Disord 2007; 7: 17. [CrossRef]
16. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007; 28: 553-9. [CrossRef]
17. Turhan H, Yaşar AS, Yaǧmur J, Kurtoǧlu E, Yetkin E. The impact of metabolic syndrome on left ventricular function: evaluated by using the index of myocardial performance. Int J Cardiol 2009; 132: 382-6. [CrossRef]
18. Wong CY, O'Moore-Sullivan T, Fang ZY, Haluska B, Leano R, Marwick TH. Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. Am J Cardiol 2005; 96: 1686-91. [CrossRef]
19. Butler J, Rodondi N, Zhu Y, Figaro K, Fazio S, Vaughan DE, et al. Health ABC Study. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006; 47: 1595-602. [CrossRef]
20. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107: 448-54. [CrossRef]
21. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73.
22. Holmäng A, Yoshida N, Jennische E, Waldenström A, Björntorp P. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest 1996; 26: 973-8. [CrossRef]
23. Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu M, et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol 2006; 291: H787-96. [CrossRef]
24. Ganguly PK, Dhalla KS, Innes IR, Beamish RE, Dhalla NS. Altered norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res 1986; 59: 684-93.
25. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-52. [CrossRef]
26. Sartori M, Ceolotto G, Papparella I, Baritono E, Ciccariello L, Calò L, et al. Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens 2004; 17: 604-10. [CrossRef]
27. Ingelsson E, Arnlöv J, Lind L, Sundström J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006; 92:1409-13. [CrossRef]
28. Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, et al. Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 2005; 48: 1229-37. [CrossRef]
29. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998; 40: 239-47. [CrossRef]
30. Govindarajan G, Hayden MR, Cooper SA, Figueroa SD, Ma L, Hoffman TJ, et al. Metabolic derangements in the insulin resistant heart. J Cardiometab Syndr 2006; 1: 102-6. [CrossRef]
31. Brownsey RW, Boone AN, Allard MF. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res 1997; 34: 3-24. [CrossRef]
32. Iozzo P, Chareonthaitawee P, Di Terlizzi M, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab 2002; 282: E1163-71.
33. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433-41. [CrossRef]
34. Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M, Regan TJ. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Ther 1998; 3: 319-26. [CrossRef]
35. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13. [CrossRef]
36. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009; 119: 44-52. [CrossRef]
37. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177-87. [CrossRef]
38. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600. [CrossRef]